1. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P,
Bankhead C, Xu Y. Anticoagulation control and prediction of adverse
events in patients with atrial fibrillation: a systematic review.
Circulation: Cardiovascular Quality and Outcomes. Nov 2008;1(2):84-91.
DOI: 10.1161/CIRCOUTCOMES.108.796185.
2. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip
GY. Cessation of oral anticoagulation in relation to mortality and the
risk of thrombotic events in patients with atrial fibrillation. Thromb
Haemost, 2013, 110: 1189-1198.
3. Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY,
Svensson PJ, Sjalander A. Safety and efficacy of well managed
warfarin. A report from the Swedish quality register Auricula. Thromb
Haemost, 2015, 113: 1370-1377.
4. Heneghan, С. et al Self-monitoring of oral anticoagulation: a
systematic review and meta-analysis Lancet 2006; 367: 404-11.
5. Syed Ghulam, Sarwar Shah, Julie Barnett, Jasna Kuljis, Kate Hone,
Richard Kaczmarski. Factors determining patients’ intentions to use
point-of-care testing medical devices for self-monitoring: the case of
international normalized ratio self-testing. Patient Preference and
Adherence, 2013:7, p.1–14 DOI: 10.2147/PPA.S38328
6. Марцевич С.Ю., Лукина Ю.В. Варфарин и его значение в эру новых
оральных антикоагулянтов. Вопросы контроля эффективности и
безопасности лечения. Рациональная Фармакотерапия в Кардиологии
2017;13(5). С.699-705.